Email: cspc@cspc.cn
Media
News Center
Jun. 28
2023
Research Results of JMT101 of CSPC Published in Subjournal of Nature
CSPC Attending Beijing-Tianjin-Hebei Pharmaceutical Innovation and Development Conference
Jun. 27
VOLUNTARY ANNOUNCEMENT - CHINA'S FIRST ANTI-GFRAL MONOCLONAL ANTIBODY JMT203 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
VOLUNTARY ANNOUNCEMENT - TEDIZOLID PHOSPHATE FOR INJECTION OBTAINS DRUG REGISTRATION APPROVAL
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF BIOLOGIC LICENSE APPLICATION OF OMALIZUMAB FOR INJECTION
Jun. 26
Strategic Cooperation between CSPC and China Unicom
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
